Last reviewed · How we verify

NCT04528511: BENEFIT-AMI

BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction

Recruiting now Last updated 19 March 2026
What this trial tests

trial testing Continuous Electronic Monitor in Atrial Fibrillation New Onset in 774 participants. Currently enrolling.

Timeline
1 October 2020
Primary endpoint
31 December 2027
30 June 2028

Quick facts

Lead sponsorShanghai 10th People's Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment774
Start date1 October 2020
Primary completion31 December 2027
Estimated completion30 June 2028
Sites5 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai 10th People's Hospital

Who can join

18 and older, any sex, with Atrial Fibrillation New Onset or Acute Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To validate the prognostic importance of the burden of new-onset atrial fibrillation (NOAF) complicating acute myocardial infarction (AMI) in a prospectively designed hospital-based registry. To characterize those factors that contribute to the progression of post-MI NOAF burden. To establish a prediction model for the risk stratification of patients with NOAF complicating AMI. To explore the clinical usefulness of NOAF burden in guiding the anticoagulation therapy among patients with post-MI NOAF.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation New Onset

Currently open trials in the same condition.

Other Shanghai 10th People's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04528511.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing